et al. (2012) Progression of non-small-cell lung cancer during the interval before stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 82: 463-467.Murai T, Shibamoto Y, Baba F et al (2010) Progression of non-small-cell lung cancer during the interval before stereotactic body ...
Non-small-cell lung carcinoma (NSCLC)circular RNA ZFR (circZFR)miR-101-3pcullin 4B (CUL4B)cell proliferationinvasionBackground: Non-small-cell lung carcinoma (NSCLC) is the most common type of lung cancer. Circular RNA ZFR (circZFR) is an identified circular RNA (circRNA) that is ...
The genetic regulation of cell cycle progression and cell proliferation plays a role in the growth of non-small cell lung cancer (NSCLC), one of the most common causes of cancer-related mortality. Although DEAD-box RNA helicases are known to play a role in cancer development, including lung ...
Non-small cell lung cancer (NSCLC) is the predominant histological subtype of lung cancer and accounts for up to 85% of all reported cases [1]. NSCLC is the leading cause of cancer deaths worldwide [2]. It is necessary to explore biomarkers or potential targets to effectively overcome NSCLC...
Circular RNAs (circRNAs) have emerged as a pivotal regulatory element in the progression of human cancers. Being an important member of circRNAs, circFOXO3 has been implicated in tumor invasion or metastasis of non-small cell lung cancer (NSCLC); however, the molecular mechanism underlying this pr...
non-small cell lung cancer (NSCLC) tissues as compared to paracarcinoma tissues. Additionally, we observed that GRIK3 expression was strongly correlated with the prognosis of NSCLC patients. We also noted that GRIK3 suppressed the cell proliferation and migration capability of NSCLC cells, thereby ...
Smoking is closely related to lung cancer, which can not only induce the occurrence of lung cancer but also affect its progress and prognosis. Objectives To investigated the relationship between smoking and 14-3-3σ protein expression in non-small-cell lung cancer (NSCLC), investigated the ...
Immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy have become the standard of care for a subset of patients with unresectable/metastatic non-small cell lung cancer (NSCLC)1. These agents are being tested in the neoadjuvant setting for patients with resectable NSCLC2 with...
et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. Cancer Res. 77, 2255–2265 (2017). Article CAS PubMed PubMed Central Google Scholar Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017). ...
SLC34A2 with highest expressions in lung, small intestine and kidney encoded a type 2b sodium-dependent phosphate transporter (NaPi-IIb). In lung, SLC34A2 only expressed in the apical membrane of type II alveolar epithelium cells (ATII cells) and played